Marseille-based biopharmaceutical firm Genoscience Pharma has made four appointments to its board of directors.
Robert Duggan, Chaim Hurvitz, Manmeet Soni and Mahkam Zanganeh will share responsibility for the financial and strategic development of Genoscience together with the four existing members of the board.
President and founder of Genoscience Professor Philippe Halfon said: “I am delighted to welcome this high caliber team to our board of directors.
“It is an honour and a true mark of recognition to be joined by such a team, who participate very selectively in high potential projects.”
Robert Dugan joins from Pharmacyclics where he recently served as chief executive officer and chairman of the board from 2009 until 2015. He held the chief executive officer role at Computer Motion, a US-based medical robotics company, between 1997 and 2003 and is currently founding principal of venture capital and securities investment firm Robert W. Duggan & Associates.
Bringing over 30 years of life sciences experience to the board, Chaim Hurvitz currently serves as chief executive officer of CH-Health, a private venture capital firm. He has held several senior management roles at Teva Pharmaceuticals, including president of Teva International Group from 2002 to 2010 and has been a member of Galmed Pharmaceutical’s board of directors since 2011.
Manmeet Soni has nearly 20 years of management experience in finance, business development, commercials operations and human resources. He most recently served as Pharmcyclics’ chief financial officer and treasurer and has also held management positions at ZELTIQ Aesthetics and PriceWaterhouseCoopers, where he worked in PwC’s San Jose office as an advisor in its life sciences and venture capital group.
Dr Mahkam Zanganeh also brings experience at Pharmacyclics to the Genoscience board having been its chief of staff and chief business officer from 2008 to 2012 and chief operating officer from 2012 to 2015. Prior to this, Dr Zanganeh has served as president director general for the French government’s bio-cluster project, vice president of business development at Robert W. Duggan & Associates and president director general EMEA at Computer Motion.